[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352541-105":59,"doc-detail-352541-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","distinct-immune-microenvironments-in-ovarian-cancer-subtypes-indicate-potential-for-immunotherapies","Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies","","Immunotherapy for ovarian cancers requires precision immune targets and patient stratification, yet rare subtypes such as low-grade serous, mucinous, clear cell, and endometrioid remain insufficiently mapped in an immuno-oncology context. Spatially resolved molecular profiling of tumor and immune proteins across 254 patients used GeoMx with multiplex immunofluorescence, combining spatial statistics, survival analysis, and machine learning to link subtype-specific immune regulation to clinically meaningful biomarkers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/distinct-immune-microenvironments-in-ovarian-cancer-subtypes-indicate-potential-for-immunotherapies/352541/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/distinct-immune-microenvironments-in-ovarian-cancer-subtypes-indicate-potential-for-immunotherapies/352541.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal for ovarian cancer immunotherapy?","Question",{"text":112,"@type":113},"To identify precision immune targets for immune priming and to support patient stratification by characterizing how immune states vary across ovarian cancer subtypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were immune and tumor features measured in this study?",{"text":117,"@type":113},"By spatially resolved molecular profiling of tumor and immune protein markers in defined tissue regions from 254 patients using GeoMx, with spatial statistics derived from multiplex immunofluorescence images.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immune markers were linked to specific ovarian cancer subtypes?",{"text":121,"@type":113},"Examples include STING in low-grade serous, CTLA-4 and PD-L1 in mucinous, CD40/IDO1/VISTA in clear cell, and B7-H3 in endometrioid ovarian carcinomas.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352541,1790194014,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Frank et al. Journal of Translational Medicine (2026) 24:337  \n[https://doi.org/10.1186/s12967-026-07879-8](https://doi.org/10.1186/s12967-026-07879-8)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nDistinct immune microenvironments   in ovarian cancer subtypes indicate potential for immunotherapies  \nAsger Meldgaard Frank1, Elias Carlsson1, Huaqiang Ouyang2, Lina Olsson1, Constantina Claudia Mateoiu3, Sara Ek 1, Karin Sundfeldt4 and Anna Gerdtsson1*  \nAbstract  \nBackground To enable immunotherapy for ovarian cancers, precision targets for immune priming as well as patient stratification approaches are required. The tumor microenvironment in particularly the rare subtypes of low-grade serous, mucinous, clear cell and endometrioid ovarian cancer, remains poorly characterized, and these tumors have been largely ignored in the immuno-oncology setting.  \nMethods We performed spatially resolved molecular profiling of 78 tumor and immune protein markers in defined tissue regions from 254 ovarian cancer patients of mixed histologies, using GeoMx. Network graph analysis was applied to compute spatial statistics from multiplex immunofluorescence images. GeoMx-compatible softwares were developed for data processing and analysis, based on linear mixed effect modelling, survival analysis and machine learning.  \nResults Immune-regulatory targets associated with specific subtypes included STING in low-grade serous; CTLA-4 and PD-L1 in mucinous; CD40, IDO1 and VISTA in clear cell; and B7-H3 in endometrioid ovarian carcinomas. In high-grade serous ovarian carcinomas, intra-tumoral expression of SMA and PD-L1 emerged as strong prognostic indicators. Proximity of CD8 + T-cells to tumor cells as measured by group degree centrality was a marker of improved prognosis and of infiltration of all T cell subtypes, dendritic cells, and tumor-associated macrophages, along with elevated expression of PD-L1, IDO1, Tim-3, and CD40 . In contrast, tumors with low CD8-tumor proximity were enriched in CD20 and CD25 .  \nConclusions Our findings highlight the potential for differential targeted treatment related to histotyping, tumorimmune spatial scoring and intra-tumoral expression of key prognostic markers.  \nKeywords Ovarian cancer, Tumor microenvironment, Immune-oncology, Spatial biology, Digital spatial profiling  \n*Correspondence:  \nAnna Gerdtsson  \n[anna.sandstrom_gerdtsson@immun.lth.se](anna.sandstrom_gerdtsson@immun.lth.se)  \n1Department of Immunotechnology, Lund University, Medicon Village 406, Scheelevägen 8, Lund 223 87, Sweden  \n2Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, Tianjin 300060, P. R. China  \n3Department of Pathology and Cytology, Sahlgrenska Academy at University of Gothenburg, Gula stråket 8 plan 0, Göteborg 41345, Sweden 4Department of Obstetrics and Gynecology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Hospital, Blå stråket 6 plan 2, Kvinnokliniken, Göteborg 41345, Sweden  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/lic","cbCaiqIyrbHrVJmu","https://ap.wps.com/l/cbCaiqIyrbHrVJmu","pdf",8169044,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Treatment heterogeneity and unmet need\n## Tumor microenvironment and immunosuppression\n## CD8 T cell infiltration and immune evasion\n## Immune checkpoint inhibition in ovarian cancer","[{\"question\":\"What was the study’s main goal for ovarian cancer immunotherapy?\",\"answer\":\"To identify precision immune targets for immune priming and to support patient stratification by characterizing how immune states vary across ovarian cancer subtypes.\"},{\"question\":\"How were immune and tumor features measured in this study?\",\"answer\":\"By spatially resolved molecular profiling of tumor and immune protein markers in defined tissue regions from 254 patients using GeoMx, with spatial statistics derived from multiplex immunofluorescence images.\"},{\"question\":\"Which immune markers were linked to specific ovarian cancer subtypes?\",\"answer\":\"Examples include STING in low-grade serous, CTLA-4 and PD-L1 in mucinous, CD40/IDO1/VISTA in clear cell, and B7-H3 in endometrioid ovarian carcinomas.\"}]","Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies | PDF",1790100188,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f62df4fdcd4f8795e5de9550d2dd84f6.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27eb11fc8c5e8ba52b7699620282b9ec.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/414f9fe4c124d8bdbd9545583279f05d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7ca4074a2ae441d4f4778acb27f59f6.webp",980,1306]